7 Ergebnisse
Sortierung:
In: Journal of consumer protection and food safety: Journal für Verbraucherschutz und Lebensmittelsicherheit : JVL, Band 4, Heft S2, S. 25-31
ISSN: 1661-5867
BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.
BASE
BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.
BASE
In: Dhami , S , Nurmatov , U , Roberts , G , Pfaar , O , Muraro , A , Ansotegui , I J , Calderon , M , Cingi , C , Demoly , P , Durham , S , van Wijk , R G , Halken , S , Hamelmann , E , Hellings , P , Jacobsen , L , Knol , E , Linnemann , D L , Lin , S , Maggina , V , Oude-Elberink , H , Pajno , G , Panwankar , R , Pastorello , E , Pitsios , C , Rotiroti , G , Timmermans , F , Tsilochristou , O , Varga , E-M , Wilkinson , J , Williams , A , Worm , M , Zhang , L & Sheikh , A 2017 , ' Erratum to : Allergen immunotherapy for allergic rhinoconjunctivitis: Protocol for a systematic review (Clinical and Translational Allergy (2016) 6 (12) DOI:10.1186/s13601-016-0099-6) ' , Clinical and Translational Allergy , vol. 7 , 29 . https://doi.org/10.1186/s13601-017-0168-5
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below: Funding EAACI and the BM4SIT project (Grant Number 601763) in the European Union's Seventh Framework Programme FP7.
BASE
In: Zuberbier , T , Abdul Latiff , A H , Abuzakouk , M , Aquilina , S , Asero , R , Baker , D , Ballmer-Weber , B , Bangert , C , Ben-Shoshan , M , Bernstein , J A , Bindslev-Jensen , C , Brockow , K , Brzoza , Z , Chong Neto , H J , Church , M K , Criado , P R , Danilycheva , I V , Dressler , C , Ensina , L F , Fonacier , L , Gaskins , M , Gáspár , K , Gelincik , A , Giménez-Arnau , A , Godse , K , Gonçalo , M , Grattan , C , Grosber , M , Hamelmann , E , Hébert , J , Hide , M , Kaplan , A , Kapp , A , Kessel , A , Kocatürk , E , Kulthanan , K , Larenas-Linnemann , D , Lauerma , A , Leslie , T A , Magerl , M , Makris , M , Meshkova , R Y , Metz , M , Micallef , D , Mortz , C G , Nast , A , Oude-Elberink , H , Pawankar , R , Pigatto , P D , Ratti Sisa , H , Rojo Gutiérrez , M I , Saini , S S , Schmid-Grendelmeier , P , Sekerel , B E , Siebenhaar , F , Siiskonen , H , Soria , A , Staubach-Renz , P , Stingeni , L , Sussman , G , Szegedi , A , Thomsen , S F , Vadasz , Z , Vestergaard , C , Wedi , B , Zhao , Z & Maurer , M 2022 , ' The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria ' , Allergy: European Journal of Allergy and Clinical Immunology , vol. 77 , no. 3 , pp. 734-766 . https://doi.org/10.1111/all.15090
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
BASE
In: Zuberbier , T , Abdul Latiff , A H , Abuzakouk , M , Aquilina , S , Asero , R , Baker , D , Ballmer-Weber , B , Bangert , C , Ben-Shoshan , M , Bernstein , J A , Bindslev-Jensen , C , Brockow , K , Brzoza , Z , Chong Neto , H J , Church , M K , Criado , P R , Danilycheva , I V , Dressler , C , Ensina , L F , Fonacier , L , Gaskins , M , Gáspár , K , Gelincik , A , Giménez-Arnau , A , Godse , K , Gonçalo , M , Grattan , C , Grosber , M , Hamelmann , E , Hébert , J , Hide , M , Kaplan , A , Kapp , A , Kessel , A , Kocatürk , E , Kulthanan , K , Larenas-Linnemann , D , Lauerma , A , Leslie , T A , Magerl , M , Makris , M , Meshkova , R Y , Metz , M , Micallef , D , Mortz , C G , Nast , A , Oude-Elberink , H , Pawankar , R , Pigatto , P D , Ratti Sisa , H , Rojo Gutiérrez , M I , Saini , S S , Schmid-Grendelmeier , P , Sekerel , B E , Siebenhaar , F , Siiskonen , H , Soria , A , Staubach-Renz , P , Stingeni , L , Sussman , G , Szegedi , A , Thomsen , S F , Vadasz , Z , Vestergaard , C , Wedi , B , Zhao , Z & Maurer , M 2022 , ' The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria ' , Allergy: European Journal of Allergy and Clinical Immunology . https://doi.org/10.1111/all.15090 ; ISSN:0105-4538
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
BASE
In: Zuberbier , T , Abdul Latiff , A H , Abuzakouk , M , Aquilina , S , Asero , R , Baker , D , Ballmer-Weber , B , Bangert , C , Ben-Shoshan , M , Bernstein , J A , Bindslev-Jensen , C , Brockow , K , Brzoza , Z , Chong Neto , H J , Church , M K , Criado , P R , Danilycheva , I V , Dressler , C , Ensina , L F , Fonacier , L , Gaskins , M , Gáspár , K , Gelincik , A , Giménez-Arnau , A , Godse , K , Gonçalo , M , Grattan , C , Grosber , M , Hamelmann , E , Hébert , J , Hide , M , Kaplan , A , Kapp , A , Kessel , A , Kocatürk , E , Kulthanan , K , Larenas-Linnemann , D , Lauerma , A , Leslie , T A , Magerl , M , Makris , M , Meshkova , R Y , Metz , M , Micallef , D , Mortz , C G , Nast , A , Oude-Elberink , H , Pawankar , R , Pigatto , P D , Ratti Sisa , H , Rojo Gutiérrez , M I , Saini , S S , Schmid-Grendelmeier , P , Sekerel , B E , Siebenhaar , F , Siiskonen , H , Soria , A , Staubach-Renz , P , Stingeni , L , Sussman , G , Szegedi , A , Thomsen , S F , Vadasz , Z , Vestergaard , C , Wedi , B , Zhao , Z & Maurer , M 2022 , ' The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria ' , Allergy: European Journal of Allergy and Clinical Immunology , vol. 77 , no. 3 , pp. 734-766 . https://doi.org/10.1111/all.15090
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
BASE
